LifeCell Corporation

Summary

Introduction

LifeCell Corporation (LifeCell) develops, processes and markets biologically-based products in the emerging field of regenerative medicine. The company's proprietary human tissue matrix has been successfully used in more than 1 million grafts and implants so far.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

LifeCell currently markets products including: AlloDerm, for plastic reconstructive, general surgical, burn and periodontal procedures; Cymetra, a particulate form of AlloDerm suitable for injection; GraftJacket, for orthopedic applications and lower extremity wounds; AlloCraftDBM, for bone grafting procedures. Total revenues of the company grew at a double-digit CAGR of 42% from $34 million in 2002 to $142 million in 2006, recording an absolute total revenue growth of +$107 million during 2002-2006. The strong performance of AlloDerm in the reconstructive market was the major growth driver of robust revenue growth during the historical period. The company's revenues are expected to record an increase at a CAGR of 25% between 2006 and 2010. During the forecast period, total revenues are estimated to grow from $141 million to $342 million.

Reasons to Purchase

Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization .

Content